Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.
MoonLake Immunotherapeutics reports clinical, regulatory and financing developments for a clinical-stage biotechnology business focused on inflammatory skin and joint diseases. Its updates center on sonelokimab (SLK), a Nanobody designed to inhibit IL-17A and IL-17F, and on programs in hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis.
Recurring news includes Phase 2 and Phase 3 trial data from VELA, VELA-TEEN, MIRA, LEDA, S-OLARIS and IZAR studies, FDA interactions and designations tied to SLK, quarterly financial results, research and development spending, equity and debt financing activity, and shareholder voting or capital-structure matters.
MoonLake Immunotherapeutics reported positive feedback on the regulatory path for the Phase 3 program of Nanobody® sonelokimab, significant improvements in ARGO Phase 2 trial, and plans to commence four additional clinical trials across dermatology and rheumatology. The company ended Q1 2024 with $547.1 million in cash and expects a cash runway to the end of 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.